Childhood and Adolescent Depression

To summarize current knowledge on depression in children and adolescents—including epidemiology, risk factors, clinical presentation, diagnosis (including disruptive mood dysregulation disorder [DMDD]), course, and treatment—to inform evidence-based practice. Pediatric depression is now recognized as a common and serious disorder that can present even in prepubertal children, with prevalence rising markedly in adolescence. Studies indicate that depression in youth is often preceded by identifiable risk factors: female sex (especially post-puberty) confers greater risk, likely due to hormonal and psychosocial factors; early-life stress and childhood maltreatment significantly increase the likelihood of depression and a more chronic, treatment-resistant course. Neurobiological research has found that depressed adolescents exhibit abnormalities in corticolimbic circuits similar to adults (e.g., hyperactive amygdala responses to negative stimuli and reduced hippocampal volumes). The introduction of disruptive mood dysregulation disorder in Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 has helped distinguish chronic, severe irritability in youth from episodic bipolar disorder. Evidence-based treatments are available: meta-analyses confirm that psychotherapies such as cognitive-behavioral therapy and interpersonal psychotherapy are effective first-line interventions for mild-to-moderate depression in youth, and antidepressant medication (particularly fluoxetine) can be beneficial in moderate-to-severe cases. Antidepressants do not appear to increase suicidal events in aggregate youth trials, although close monitoring is advised. Childhood and adolescent depression is a prevalent and impairing psychiatric illness with potential long-term consequences. Early-onset depression often portends a more protracted, recurrent course than adult-onset depression, with a greater risk of persistence into chronic adult depression if not effectively treated. Timely recognition and intervention—including careful diagnostic assessment to differentiate depression from other conditions (such as bipolar disorder or DMDD)—are critical. A comprehensive treatment approach, typically combining developmentally tailored psychotherapy with pharmacotherapy when needed, can substantially improve acute outcomes and may alter the trajectory of illness. Ongoing research is focusing on refining preventive strategies, identifying biomarkers of risk, and optimizing treatments to improve long-term outcomes for depressed youth.